PACIFIC EDGE LTD NPV
NZX
NZ Flag
PEB

PEB
PACIFIC EDGE LTD NPV
NZ Flag
NZX
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

PEB Stock Chart

Data for NZX is only available to registered users

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: ---
Pacific Edge Limited is a cancer diagnostics company. The Company develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The Company's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. It offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Help Center Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing TradingView Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out